

(19)



(11)

EP 3 143 047 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:

07.09.2022 Bulletin 2022/36

(45) Date of publication and mention of the grant of the patent:

20.07.2022 Bulletin 2022/29

(21) Application number: **15724070.6**

(22) Date of filing: **15.05.2015**

(51) International Patent Classification (IPC):

C07K 16/28^(2006.01) A61K 39/395^(2006.01)

(52) Cooperative Patent Classification (CPC):

A61P 3/00; A61P 7/00; A61P 7/04; A61P 9/00;
A61P 13/12; A61P 17/00; A61P 17/02;
A61P 19/02; A61P 21/00; A61P 21/04;
A61P 25/00; A61P 29/00; A61P 35/00;
A61P 37/00; A61P 37/02;

(Cont.)

(86) International application number:

PCT/IB2015/053602

(87) International publication number:

WO 2015/173782 (19.11.2015 Gazette 2015/46)

(54) **BELIMUMAB FORMULATION**

BELIMUMAB FORMULIERUNG

FORMULATION DE BELIMUMAB

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **16.05.2014 US 201461994427 P**

18.12.2014 US 201462093734 P

22.12.2014 US 201462095181 P

(43) Date of publication of application:

22.03.2017 Bulletin 2017/12

(60) Divisional application:

19185861.2 / 3 715 371

20150351.3 / 3 719 038

(73) Proprietors:

- **GlaxoSmithKline Intellectual Property Management Limited**
Brentford, Middlesex TW8 9GS (GB)
- **GlaxoSmithKline Intellectual Property Limited**
Brentford, Middlesex TW8 9GS (GB)

(72) Inventors:

- **BLAKE-HASKINS, Angela**
Gaithersburg, Maryland 20878 (US)

• **MARSHALL, Tristan**

Rockville, Maryland 20850 (US)

• **O'BERRY, Kristen**

Gaithersburg, Maryland 20878 (US)

• **PERKINS, Melissa D.**

McPherson, Kansas 67460 (US)

(74) Representative: **Lee, Alison Lesley et al**

GlaxoSmithKline

Global Patents (CN925.1)

980 Great West Road

Brentford, Middlesex TW8 9GS (GB)

(56) References cited:

WO-A1-2014/114651 WO-A2-03/016468

WO-A2-03/039485 WO-A2-2006/083689

WO-A2-2012/076670

- **April ET AL: "product monograph BENLYSTA TM", , 16 April 2014 (2014-04-16), XP055203701, Retrieved from the Internet:**
URL: <http://www.gsk.ca/english/docs-pdf/product-monographs/Benlysta.pdf> [retrieved on 2015-07-21]

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 143 047 B8

- **WANG W ET AL: "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 96, no. 1, 1 January 2007 (2007-01-01), pages 1-26, XP009084505, ISSN: 0022-3549, DOI: 10.1002/JPS.20727**

(52) Cooperative Patent Classification (CPC): (Cont.)
A61P 37/08; C07K 16/244; C07K 16/2875